… Reckamp KL, Krysan K, Morrow JD, et al: A phase I trial to determine the optimal biological
dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin …

… advanced non-small ceil lung cancer (NSCLC). Numerous … Notably, a combination of weekly
docetaxel with celecoxib … Intermittent erLotinib in combination with docetaxeL (DOC): phase …

… trials and treatments have focused mainly on non-small cell … celecoxib in combination
with EGFR TKI (erlotinib). This … for non-small cell lung cancer: a phase II study with biological …

… Further studies are required to assess the usefulness of this biomarker to identify … a phase
1 trial focused on defining the optimal biologic dose of celecoxib in combination with erlotinib, …

… valuable information about the biology of lung cancer. Outside of … phase I-II study is exploring
the combination of erlotinib and … , in a randomized phase II trial comparing celecoxib with or …

… in combination with multiple biologic agents. With continued … Intermittent erlotinib in
combination with docetaxel (DOC): phase I … with celecoxib for advanced non-small cell lung …

… on how these mutations affect the biology of lung cancer, it is possible that we may be … study
(1) erlotinib plus chemotherapy in combination with radiation and (2) erlotinib plus celecoxib…

… Finally, a dose-finding study combining celecoxib with erlotinib in 22 patients with advanced
NSCLC … The optimal biologic dose of celecoxib, based on maximal decrease in urinary …

… The primary study objective was to determine the maximum … , biological therapy, or
immunotherapy for stage IIIB/IV disease… to combination therapy with erlotinib and celecoxib in …

… In a phase I study of erlotinib evaluating several … To establish the optimal biologic dose
of endostatin, a phase … results of phase II study evaluating the combination of celecoxib and …